Published in OBGYN and Reproduction Week, July 25th, 2005
The company has begun a U.S. phase 2 clinical trial evaluating the dosing, safety and activity of TH-070 for the treatment of symptomatic benign prostatic hyperplasia (BPH). A phase 3 multi-center European trial evaluating the safety and efficacy of TH-070 is expected to commence in mid-2005.
BPH is a non-cancerous enlargement of the prostate that affects over 54 million men worldwide and at least 17 million men over the age of 40 in the United...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of OBGYN and Reproduction Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.